Brain and Spine Institute. France: Researchers from the “Experimental therapeutics of
neurodegeneration” team led by Etienne Hirsch at the Brain and Spine
Institute – ICM, Institut du Cerveau et de la Moelle épinière – and
collaborators, have just published a work that represents a real jump
forward in the fight against neurodegenerative diseases.
This work
published in Nature Communications – October 21, 2014 –
evidences a small peptide of viral origin which seems to protect
Parkinson’s disease affected neurons against degeneration. These major
advances appear very promising for the development of future therapeutic
applications in the prevention of Parkinson’s disease and more broadly,
of neurodegenerative diseases.
Background
Neurodegeneration at cell level:
The progressive loss of structure and function of neurons in
neurodegenerative diseases, including Parkinson’s disease, involves mitochondrial dysfunction and early axonal degeneration
prior to death of cell body – axons being neurons extensions leading
the electric signal from cell body toward synaptic areas. Mitochondria –
the powerhouse of the cells – are small organelles (about 1 micrometer)
inside cells, essential in cellular energy production and whose
physiological role is crucial. When mitochondria are impaired,
degeneration and progressive loss of axons is observed with a subsequent
neuronal death. Consequently, agents that protect mitochondria have
strong therapeutic potential.
Clever viruses that hijack cellular functions with maintaining host cell alive:
Different viruses and other pathogens are known to hijack cellular
pathways to their advantage in order to survive and replicate in their
host. A case in point is Borna disease virus (BDV), a
neurotropic virus that infects nerve cells and persists in nerve tissue
without damaging cells. Survival and replication of BDV in neurons
depends in part on a viral protein – the X protein – that it produces and that accumulates in mitochondria where it exerts an anti-apoptotic effect (cell death inhibition), ensuring the maintenance of BDV habitat.
In view of this background, in collaboration with the team of Daniel Gonzalez-Dunia at the Purpan Physiopathology Center of Toulouse (CPTP) * and of Jean-Michel Peyrin at the Institut de Biologie Paris Seine**, Stéphane Hunot and Yann Monnet from Etienne Hirsch’s team at the ICM, were tempted to investigate whether the X protein could protect neurons against neurodegenerative insults.
Mitochondia – cell organel – the powerhouse of the cells © INSERM/Torpier, Gérard
Research advances
Diversion of natural strategy used by BDV virus – X peptide:
Authors show that, alone, outside of the viral context, the BDV X
protein has strong protective properties for axons through a
mitochondrial maintaining mechanism, thereby protecting neurons from
degeneration. Neuro-protective effect of this protein was validated both
in vitro tissue culture and in an animal model of Parkinson’s disease.
Intracranial injection of a lentiviral vector driving the expression of
the BDV X, markedly reduced axonal damage and neuronal loss of
dopaminergic neurons – lesion of which is involved in Parkinson’s
disease. Even more interesting, these neuro-protective effects –
currently tested in mice – also operate via intranasal
administration of a cell-permeable peptide derived from the X protein
which passes through cell membranes and localizes to mitochondria. This
relatively minimally invasive method holds great promise for future
therapeutics.
The identification of this neuro-protective peptide and the very
promising study results of which he has been the subject, open the way
to novel therapies for neurodegenerative diseases, such as Parkinson’s
or Alzheimer’s, by targeting mitochondrial dynamics and thus preventing
the earliest steps of neurodegenerative processes in axons.
X Peptide intranasal administration protects from neurodegeneration
in a Parkinson animal model © Yann Monnet/Marion Szelechowski –
Nature Communications
Scientific article:
A viral peptide that targuets mitochondria protects against neuronal degenereation in models of Parkinson’s disease, Marion Szcelechowski et al., Nature Communication (online publication 21 October 2014)
Link to the publication
Collaborators :
* Centre de Physiopathologie de Toulouse Purpan (CPTP), INSERM UMR 1043, CNRS UMR 5282, Université Toulouse III Paul Sabatier.
** Biological Adaptation an Ageing, CNRS UMR 8256, Institut de Biologie Paris Seine, Sorbonne Universités, UPMC.